Today’s Highlights- Prohost Biotech - Exclusive Biotech Research

Category: Today’s Highlights

Jounce Therapeutics Inc Achieves First Milestone in Exclusive License Agreement with Gilead Sciences for JTX-1811

Jounce Therapeutics Inc: US FDA Cleared IND Application for JTX-1811 Targeting CCR8 Jounce Therapeutics Inc ( JNCE ) - a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced that the U.S. Food...

June 15, 2021

Why Travere Therapeutics' Stocks Did Not Fall During This Tuesday's Bad Market

The Bear Market The volatility in the Bear stock market continues to plunge the values of biotech stocks. The Bear market is sucking investors’ capitals who bet on firms with future growth potential based on early, mid term and late...

February 22, 2023

Regeneron Pharmaceuticals EYLEA HD Approved by FDA for Wet Age-related Macular Degeneration, Diabetic Macular Edema and Diabetic Retinopathy

Regeneron Pharmaceuticals EYLEA HD Approved by the FDA Regeneron Pharmaceuticals ( REGN ) announced that the U.S. FDA has approved EYLEA HD ( aflibercept ) Injection 8 mg for the treatment of patients with wet age-related macular degeneration ( wAMD ),...

August 21, 2023

Intellia Therapeutics Announces FDA Clearance of IND Application for NTLA-2002 Therapy for the Treatment of Hereditary Angioedema

Intellia Therapeutics Intellia Therapeutics ( NTLA ) announced that the U.S. FDA has cleared the company’s Investigational New Drug ( IND ) application for NTLA-2002. About NTLA-2002 Based on Nobel Prize-winning CRISPR/Cas9 technology, NTLA-2002 is the first single-dose investigational treatment. NTLA-2002...

March 2, 2023

Arcus Biosciences Participates in Multiple Upcoming Investor Conferences. The Stock is Boosted. See Also: Today’s Roche Press Release

Arcus Biosciences Arcus Biosciences ( RCUS ) is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer and chronic inflammatory diseases, and other diseases. In partnership with firms and physicians around the world, Arcus...

August 23, 2023

Halozyme Therapeutics ENHANZE Reduces Roche's Tecentriq® Treatment Time to 7 Minutes from 30-60

Halozyme Therapeutics in the NEWS Halozyme Therapeutics ( HALO ) announced today that the Medicines and Healthcare Products Regulatory Agency ( MHRA ) in Great Britain has approved Roche's ( RHBBY ) subcutaneous Tecentriq® SC (atezolizumab), using Halozyme's ENHANZE® drug...

August 29, 2023

Crinetics Pharmaceuticals: Once Daily, Oral Investigational Product Met Primary and Secondary Endpoints in Phase 3 Treatment of Acromegaly

Crinetics Pharmaceuticals Once Daily, Oral Treatment for Acromegaly Crinetics Pharmaceuticals ( CRNX ) announced that its oral and once daily investigational compound paltusotine achieved positive results by meeting the primary endpoint and all secondary endpoints of the Phase 3 PATHFNDR-1...

September 11, 2023

Neurocrine Biosciences: Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia

Neurocrine Biosciences in the NEWS Today, Neurocrine Biosciences ( NBIX ) announced positive top-line data from Phase 3 CAHtalystTM Adult Study evaluating the efficacy, safety, and tolerability of crinecerfont in adults with classic congenital adrenal hyperplasia ( CAH ) due...

September 12, 2023

Blackstone Announces the Launch of a New Company with Intellia Therapeutics and Cellex Cell Professionals GmbH

Blackstone Life Sciences, Intellia Therapeutics and Cellex Cell Professionals New Company Blackstone ( BX ) announced that funds managed by Blackstone Life Sciences have committed $250 million towards the launch of a new autologous and allogeneic universal chimeric antigen receptor...

June 22, 2021

Halozyme Therapeutics Good News About Approvals. See Also: Arrowhead Pharmaceuticals Good Trial Results for Liver Diseases

Halozyme Therapeutics Approvals for DARZALEX ® SC Halozyme Therapeutics ( HALO ) announced that the European Commission ( EC ) has granted Janssen Pharmaceutical Companies of Johnson & Johnson two marketing authorizations for the subcutaneous formulation of daratumumab, known as...

June 23, 2021

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024